Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial.
What's New
Fulzerasib plus cetuximab achieved a 69% confirmed objective response rate as first-line therapy in KRASG12C-mutated non-small-cell lung cancer.
Detailed Summary
A single-arm, multicentre, phase 1b/2 trial across Spain, Italy, and Greece treated 47 patients with previously untreated KRASG12C-mutated advanced NSCLC with fulzerasib plus cetuximab. The confirmed objective response rate was 69% (90% CI 56-80) at a median follow-up of 12.8 months, with grade 3 treatment-related adverse events occurring in 15% and no grade 4 or 5 events observed.
Study Population
Adults aged 18+ with treatment-naive KRASG12C-mutated advanced or metastatic NSCLC (n=47; median age 68 years; 53% male, 47% female)
This research is for informational purposes only — discuss with your doctor before making any changes to your care.
Rivvet may earn a referral fee if you book through this link.
Discussion
Loading comments...
Comments are public. Be respectful and remember: this is not medical advice. Do not share personal health information.